Tsumura

Basic Information

Stock Code
4540
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
April 1936
Listing Year
August 1978
Official Website
https://www.tsumura.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Yakult, Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharmaceutical, Eisai, Rohto, Ono Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings, Kose

Overview

Tsumura is a leading Kampo medicine manufacturing company established in 1936, holding approximately 80% market share of prescription Kampo medicines in Japan.

Current Situation

Tsumura recorded consolidated sales of nearly ¥180 billion in the fiscal year ending March 2025 and is the top manufacturer with over 80% domestic share of prescription Kampo formulations. Following a financial institution scandal, it restructured to specialize in prescription Kampo medicines, spinning off and selling the household products division. It has procurement and manufacturing bases in China, Laos, and elsewhere to stably secure global crude drug resources. Under President Terukazu Kato, it focuses on productivity improvements via digital technologies like AI quality inspections. It promotes market expansion through Kampo dissemination to medical institutions and university lectures while building a sustainability-conscious procurement system. It continues Kampo R&D, aiming for domestic and international business growth and brand strengthening. Risks include rising China base costs and drug regulation changes. Amid competition from industry giants, it maintains its Kampo-specialized strategy.

Trivia

Interesting Facts

  • Tsumura holds over 80% share of Japan's prescription Kampo medicines.
  • Founded in 1893, started as a Kampo pharmacy in Nihonbashi.
  • Bath additive Bathclin was once a Tsumura product but spun off.
  • In 1988, name changed from Tsumura Juntendo Co., Ltd. to Tsumura.
  • Industry pioneer in early scientific validation of Kampo medicines.
  • Operates crude drug cultivation and procurement bases in China and Laos.
  • Actively supports university lectures on Kampo medicine etc. for dissemination.
  • Advancing tech innovation with AI in quality testing.
  • Long operates Kampo research institute and medicinal herb garden.
  • Achieved focused business strategy specialized in Kampo medicines.

Hidden Connections

  • Kampo extract formulation technology developed by Tsumura has widely influenced other companies.
  • Bathclin's bath additives originated in the Tsumura era, leading to current product lineup.
  • Deep historical and academic ties exist between Tsumura founding family, medical professionals, and researchers.
  • Alliance with Ping An Insurance is accelerating entry into China's medical market.

Future Outlook

Growth Drivers

  • Ongoing expansion of prescription Kampo demand domestically and internationally
  • Deepening scientific evidence-based Kampo research
  • Aggressive Asia market expansion and alliance strengthening
  • Production efficiency improvements via AI and digital tech
  • Sustainable material procurement and eco-friendly product development

Strategic Goals

  • Maintain and expand domestic Kampo share
  • Achieve over 30% sales ratio in global markets
  • Efficiency gains via DX in quality control and production
  • Complete sustainable crude drug procurement system
  • Expand new Kampo formulations and meet medical needs

Business Segments

Kampo Medicine Supply to Medical Institutions

Overview
Business segment providing stable supply and services of prescription Kampo medicines.
Competitiveness
Overwhelming market leadership with over 80% domestic share in prescription Kampo
Customers
  • Hospitals
  • Clinics
  • Dispensing Pharmacies
  • Physicians
  • Healthcare Professionals
Products
  • Prescription Kampo Formulations
  • Kampo Extracts
  • Prescription Ointments

Crude Drug Procurement and Processing

Overview
Procurement and processing operations ensuring stable domestic and international crude drug supply.
Competitiveness
Stable supply system via procurement bases in China, Laos, etc.
Customers
  • Pharmaceutical Companies
  • Raw Material Suppliers
  • Quality Control Organizations
Products
  • Dried Crude Drugs
  • Extract Powders
  • Processed Kampo Raw Materials

Research and Development

Overview
R&D division advancing scientific research and new product development for Kampo medicines.
Competitiveness
Research capabilities fusing Kampo tradition and science
Customers
  • Medical Research Institutions
  • Academic Institutions
  • Pharmaceutical Manufacturers
Products
  • New Kampo Formulations
  • Quality Improvement Technologies
  • Safety Evaluations

Sales Support and Dissemination Activities

Overview
Conducts Kampo dissemination promotion and sales support activities.
Competitiveness
Specialized knowledge and networks focused on prescription Kampo
Customers
  • Medical Institutions
  • University Lectures
  • Kampo Promotion Groups
Products
  • Educational Materials
  • Medical Seminars
  • Information Services

Competitive Advantage

Strengths

  • Overwhelming position with over 80% domestic share in prescription Kampo formulations
  • High technological capabilities in scientifically researching Kampo medicines
  • Stable crude drug raw material procurement network
  • Numerous subsidiaries and production bases domestically and internationally
  • Brand strength backed by long history
  • Advanced technology utilization like AI in quality control
  • Strong sales channels to medical institutions
  • Clear business strategy specialized in Kampo medicines

Competitive Advantages

  • Maintains top share in Kampo field, overwhelming competitors
  • Integrated system from raw material production to manufacturing in China and Laos
  • Exerts leadership through information provision and education to healthcare professionals
  • Business concentration and efficiency via spin-off of bath additives etc.
  • Productivity improvement through AI-automated quality testing
  • Promotes prescription Kampo expansion via university lectures etc.
  • Pioneering scientific evidence research for Kampo ahead of major competitors
  • Diverse Kampo formulation lineup with reliable drug approvals

Threats

  • Market impact risks from drug regulation changes
  • Political and natural environment risks in raw material procurement regions
  • Profit pressure from rising China base operating costs
  • Intensifying competition with other major pharmaceutical manufacturers
  • Kampo market growth slowdown and generic impacts
  • Market demand fluctuations from health trend changes
  • Potential procurement cost increases from exchange rate fluctuations
  • Demand decline from changes in medical institutions' prescribing behavior

Innovations

2023: Introduced AI Automation Robots for Quality Testing

Overview
Advanced testing automation using machine learning in quality control processes.
Impact
Improved testing accuracy and significant production efficiency gains

2022: Strengthened New Kampo Formulation Development

Overview
Promoting R&D of new Kampo prescriptions to meet medical needs.
Impact
Expanded treatment applications and enriched product lineup

2024: Enhanced Sustainable Crude Drug Procurement

Overview
Expanded environmentally considerate crude drug cultivation and procurement systems.
Impact
Contributes to stable supply and improved corporate image

2021: Capital and Business Alliance with Ping An Insurance (China)

Overview
Strategic alliance to further strengthen expansion into China market.
Impact
Expanded sales network and capital strengthening in China

Sustainability

  • Promoting sustainable cultivation technologies for Kampo crude drugs
  • Introducing environmental and social consideration standards in crude drug procurement
  • Promoting renewable energy use and energy-saving measures
  • Participating in environmental conservation activities in collaboration with local communities
  • Ensuring fair labor environments and human rights policies